Notice of fundraising

2024/11/11

PeptiStar Inc. (Head office: Settsu City, Osaka; President: Shinichiro Fujiie; hereinafter
‘PeptiStar’) has raised a total of JPY 2,600 million through a third-party allotment of new
shares with Sumitomo Chemical Co., Ltd, Toagosei Co., Ltd, Shionogi Inc. and Sekisui
Chemical Co., Ltd. as the subscribers. PeptiDream Inc. has also acquired shares in the
company held by some existing shareholders such as INCJ.

PeptiStar is a CDMO for peptides, nucleic acids and PDC* APIs that supports the CMC of
clinical and commercial APIs by strategically integrating various cutting-edge
technologies in Japan and promoting efficiency in the supply chain, which is a bottleneck
in research and development.

Sumitomo Chemical launched a contract manufacturing business for nucleic acid
pharmaceuticals in 2013 and has established technology to chemically synthesize and
mass-produce high-purity guide RNA (gRNA) required for genome editing therapy.
With this, Sumitomo Chemical aims to become a frontrunner in the contract
manufacturing of gRNA. Through the capital alliance with Sumitomo Chemical,
PeptiStar will strengthen its stable supply system for gRNA and respond to the diversifying
technological needs for gRNA in the future by integrating the technologies of the two
companies.

Toagosei is also aiming for the early commercialization of a drug delivery system (DDS)
using the cell membrane-permeable peptide “nucleolarone” and will contribute to the
creation of a new modality by building a strong collaborative structure through the capital
alliance.

*Peptide Drug Conjugation